TEVA reports better-than-expected third-quarter results, beating both earnings and sales estimates. However, the stock declines 7%.

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...